

**AMENDMENTS TO THE CLAIMS**

Please replace all previous listings, and versions, of the claims with the following claims, where text to be added is indicated by underlining.

1-38. (Cancelled)

39. (Currently amended) A kit for treating inflammation, autoimmunity, transplant rejection, an allergic condition, or a T cell cancer by inducing apoptosis of activated T cells, comprising:

a homo-multimeric anti-P-Selectin Glycoprotein Ligand-1 (PSGL-1) antibody selected based on its ability both to bind specifically to PSGL-1 on the surface of an activated T cell and to induce apoptosis of the activated T cell, wherein the homo-multimeric anti-PSGL-1 antibody comprises two polypeptide chains, each of the polypeptide chains comprising (i) a binding domain that binds to PSGL-1, and (ii) a heterologous amino acid sequence, wherein the polypeptide chains are linked via the heterologous amino acid sequence to form the homo-multimeric anti-PSGL-1 antibody; and

instructions for use of the homo-multimeric anti-PSGL-1 antibody to treat inflammation, autoimmunity, transplant rejection, an allergic condition, or a T cell cancer.

40. (Previously Presented) The kit according to claim 39, wherein the homo-multimeric anti-PSGL-1 antibody is a chimeric anti-PSGL-1 antibody.

41. (Previously Presented) The kit according to claim 39, wherein the homo-multimeric anti-PSGL-1 antibody is a humanized anti-PSGL-1 antibody.